Pre-clinical and clinical scientific endeavours provide complementary perspectives on fundamental biological processes of translational value. Harnessing the information value on the totality of such knowledge requires novel approaches to integrate across the breadth of experimental space. High-throughput screens are often the first step on this bridge to the patient. However, their representative capacity to encompass all the cellular contexts encountered in a patient are often limited due to experimental constraints. Thus, we present PerturbX, a new deep learning model to predict transcriptional responses to chemical or genetic perturbations in unobserved cellular contexts, and to uncover interpretable factors of variation associated with the predicted response. PerturbX can be applied in both an unimodal or multimodal setting. We believe that our proposed approach has the ability to inform novel biomarker discovery and contribute to a redefinition of the drug development pipeline.